尿激酶治疗急性脑梗死临床研究

Clinical study of urokinase in the treatment of acute infarct

目的 :探讨尿激酶静脉溶栓治疗急性脑梗死的疗效。方法 :采用尿激酶 30万U加入 0 .9%生理盐水 2 5 0ml ,每日静脉滴注 ,连续 5d ,改为尿激酶10万U ,连用 5～ 10d。结果 :神经功能缺损评分 :治疗后 5d与治疗前无明显差异 (P >0 .0 5 ) ,治疗后14d与治疗前有显著性差异 (P <0 .0 5 ) ;生活能力状况 :治疗后 5d、14d与治疗前比较有极显著性差异 (P <0 .0 1) ;临床疗效评定 :治疗后 5d显效率4 2 .86 %,治疗后 14d显效率 71.4 3%,两组有极显著性差异 (P <0 .0 1) ;纤维蛋白原、全血还原粘度 :治疗后 5d、14d与治疗前相比均有显著性差异 (P<0 .0 1)。结论 :尿激酶静脉溶栓治疗急性脑梗死安全、有效 ,方法简便、快捷。严格选择病例 ,监测凝血象、血小板等指标 ,并发症可避免或减少。

AIM: To explore the efficacy of urokinase used intravenously in the treatment of acute infarct. METHODS: Urokinase of 300 thousand units were added to 250 ml 0.9% normal saline intravenously, lasting for 5 days, and then changed to 100 thousand units for 5-10 d. RESULTS: The assessment of neurologic dysfunction as follows: there were no significant difference after 5 day treatment as compared with pretreatment (P>0.05), and significant difference was noticed after 14 day treatment as compared with pretreatment (P< 0.05). The status of life ability as follows: there were much significant difference after 5 day and 14 day treatment as compared with pretreatment (P< 0.01). The clinical efficacy: the ratio of showing-effect was 42.86% after 5 day treatment, and 71.43% after 14 day treatment, and there were much significantly difference between those two groups. The fibrinogen and blood deoxidized viscosity: there were significantly difference after 5 day and 14 day treatment as compared with pretreatment (P< 0.01). CONCLUSION: It is safe, effective, convenient for urokinase to treat acute infarct used intravenously, and the side effects can be avoided or reduced.